Zai Lab Limited SEC Filings

Zai Lab Ltd disclosed insider share movements by its chairperson and CEO, who is also a director. On December 10, 2025, the insider made a bona fide gift of 303,378 American Depositary Shares (ADSs) at a reported price of $0, leaving 586,641 ADSs beneficially owned afterward. On December 11, 2025, the insider received 377,520 ADSs, also at $0, as an annuity payment from the same grantor retained annuity trust, increasing beneficial ownership to 964,161 ADSs. Each ADS represents ten Ordinary Shares of Zai Lab, and the ADSs and Ordinary Shares are described as fully fungible.

Zai Lab Ltd (ZLAB) reported an insider stock sale by its Chief Legal Officer. On 11/21/2025, the officer sold 14,328 American Depositary Shares (ADS) of Zai Lab in an open-market transaction coded as an "S" sale at a price of $19.78 per ADS. After this transaction, the officer beneficially owned 27,737 ADS, held directly.

Each ADS represents ten Ordinary Shares of Zai Lab, and the ADSs and Ordinary Shares are described as fully fungible. The filing notes that the trade was carried out under a Rule 10b5-1 trading plan adopted by the reporting person on 11/22/2024, indicating it was pre-arranged under that rule’s affirmative defense framework.

Zai Lab Limited reported Q3 2025 results showing higher sales and a narrower loss. Total revenues were $116.1 million (up 14% year over year), driven by net product revenue of $115.4 million. The company posted a net loss of $36.0 million, improving from a $41.7 million loss a year ago, with basic and diluted loss per share of $0.03.

Growth was led by NUZYRA $15.4M (+54% YoY), OPTUNE $12.7M (+64% YoY), and contributions from XACDURO $6.4M and AUGTYRO $1.7M, while ZEJULA $42.4M declined 12% amid class competition. R&D expenses fell to $47.9M (down 27%), reflecting lower licensing fees, and SG&A was $70.1M. Cash and cash equivalents were $717.2 million as of September 30, 2025; short‑term debt was $203.0 million. Shares outstanding were 1,105,937,600 as of October 31, 2025.

Zai Lab Limited filed a Form 8-K stating it furnished a press release announcing its third-quarter 2025 financial results. The press release is included as Exhibit 99.1 and is provided under Item 2.02 (Results of Operations and Financial Condition). The information is furnished and not deemed filed under the Exchange Act. The company’s ADSs, each representing 10 ordinary shares, trade on Nasdaq under ZLAB, with ordinary shares listed in Hong Kong under 9688.

Zai Lab (ZLAB) disclosed insider activity by its Chief Financial Officer. On 10/31/2025, 500 American Depositary Shares (ADS) were acquired upon the vesting of restricted share units (RSUs). On 11/03/2025, 240 ADS were sold at $26.831 per ADS to cover taxes associated with the vesting. Following these transactions, the officer directly owned 17,444 ADS.

Each ADS represents ten Ordinary Shares. Each RSU represents a contingent right to receive one ADS, with the grant vesting in equal annual installments over four years beginning on 11/01/2022.

Zai Lab Limited entered into a maximum amount guarantee and established a revolving credit facility to support working capital in mainland China. The company will guarantee working capital loans of up to RMB300 million (approximately $42.1 million) from Industrial Bank Co., Ltd., Shanghai Gubei Branch, to its wholly owned subsidiary, Zai Lab (Shanghai) Co., Ltd.

The RMB300 million revolving credit facility is available until May 5, 2026. Each working capital loan is expected to have a one‑year term, with specific amounts, terms, and interest rates set in loan‑level documents. The credit line includes customary representations, warranties, and covenants, including a requirement to obtain prior written consent from the lender for transactions that could adversely impact debt repayment ability, such as mergers, spin-offs, equity transfers, external investments, or substantial debt increases.

As of this report, Zai Lab Shanghai has not entered into any working capital loans under the facility.

Chen Yajing, Chief Financial Officer of Zai Lab Ltd (ZLAB), reported the vesting and partial automatic sale of restricted share units. On 10/01/2025 she had 920 ADS vest (each ADS represents ten ordinary shares), increasing her beneficial ownership to 17,640 ADS. On 10/02/2025 456 ADS were sold at $34.247 per ADS to cover taxes, leaving 17,184 ADS beneficially owned. The RSUs vest in equal annual installments over five years beginning 10/01/2022, and vested ADS are delivered following vesting.

Zai Lab Ltd (ZLAB) filed a Form 144 reporting a proposed sale of 456 American Depositary Shares (ADS) with an aggregate market value of $15,616.6810/02/2025 through Fidelity Brokerage Services on NASDAQ. The ADS were acquired on 10/01/2025 via restricted stock vesting and were paid as compensation. The filer also disclosed two prior sales in the last three months: 4,096 ADS sold on 08/08/2025 for $139,304.96 and 1,438 ADS sold on 08/15/2025 for $50,931.59. Total shares outstanding reported are 421,725,450. The filing includes the standard representation that the seller is unaware of any undisclosed material adverse information.

Du Ying, Chairperson & CEO and a director of Zai Lab Ltd (ZLAB), reported insider transactions dated 08/29/2025. The filing shows an acquisition of 604,376 American Depositary Shares (ADSs) at a price of $1.20 per ADS, increasing reported beneficial ownership to 1,141,338 ADSs. The filing also records a disposition of 251,319 ADSs at $32.59 per ADS, leaving 890,019 ADSs reported as beneficially owned after the transactions. The Form 4 discloses that each ADS represents ten ordinary shares and that the stock options underlying the reported acquisition fully vested on March 9, 2021. The form is signed by an attorney-in-fact on behalf of the reporting person on 09/03/2025.